I will admit...

...that the meteoric rise in $IBB (the biotech sector ETF) has me a little nervous, particularly in our position in Galectin Therapeutics ($GALT) which has doubled in price largely due to the momentum of IBB and Intercept Pharmaceuticals (ICPT, the successful competitor of $GALT) dragging GALT up without any material change in the likelihood of success of GALT's GR-MD-02. I'm actually thinking about removing GALT from the model portfolio, but still following it in this blog, because I'm getting nervous of just how far it has ran (and the fact that in my model portfolio, our official open date was just a few days ago, the mid-teens, rather than a few months ago when GALT was below $10 price per share). Something I will ponder over the weekend.